Cationic nanoparticles for cancer therapy

Expert Opinion on Drug Delivery

Volumn 7, Issue 7, 2010, Pages 795-809

  Bilensoy, Erem ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cationic polymer; Chitosan; Complement activation; Cyclodextrin polymers; Cytotoxicity; Dendrimers; Nanoparticles; Pharmacokinetics; Poly L lysine; Polyethylene imine; Polymethacrylates

Indexed keywords

CATION; CATIONIC NANOPARTICLE; CHITOSAN; CISPLATIN; DENDRIMER; IMIDAZOLE DERIVATIVE; NANOPARTICLE; PLASMID DNA; POLYETHYLENEIMINE; POLYLYSINE; POLYMETHACRYLIC ACID; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

AREA UNDER THE CURVE; CANCER RESEARCH; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHARMACEUTICAL ENGINEERING; REVIEW; NEOPLASMS;

ANTINEOPLASTIC AGENTS; CATIONS; DRUG DELIVERY SYSTEMS; NANOPARTICLES; NEOPLASMS;

EID: 77953856405     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2010.485983     Document Type: Review

References (143)

1. Stewart BW, Kleihues P. World Cancer Report. IARC Nonserial Publication; 2003
2. Pathak P, Kathiyar VK. Multi-functional nanoparticles and their role in cancer drug delivery- a review. J Nanotechnol Online 2007;3:1-17
3. Luo Y, Prestwich GD. Cancer-targeted polymeric drugs. Curr Cancer Drug Targets 2002;2:209-226
4. Bharali DJ, Khalil M, Gurbuz M, et al. Nano particles and cancer theraphy: a concise review with emphasis on dendrimers. Int J Nanomed 2009;4:1-7
5. Jain RK. Delivery of novel therapeutic agents in tumors-physiological barriers and strategies. J Natl Cancer Inst 1989;81:570-576
6. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001;46:149-168
7. Baker JR Jr, Choi Y. Targeting cancer cells with DNA-Assembled Dendrimers a mix and match strategy for cancer. Cell Cycle 2005;4:669-671
8. Kim KY. Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomed Nanotechnol Biol Med 2007;3:103-110
9. Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm 2009;71:445-462
10. DeSmedt SC, Demeester J, Hennink WE. Cationic polymer based gene delivery systems. Pharm Res 2000;17(2):113-126
11. Anderson DG, Akinc A, Hossain N, Langer R. Structure/property studies of polymeric gene delivery using a library of poly(beta-amino esters). Mol Ther 2005;11(3):426-434
12. Anderson DG, Peng W, Akinc A, et al. A polymer library approach to suicide gene therapy for cancer. Proc Natl Acad Sci USA 2004;101(45):16028-16033
13. Green JJ, Shi J, Chiu E, et al. Biodegradable polymeric vectors for gene delivery to human endothelial cells. Bioconjug Chem 2006;17(5):1162-1169
14. Hu-Lieskovan S, Heidel JD, Bartlett DW, et al. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005;65(19):8984-8992
15. Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004;32(19):e149
16. Urban-Klein B, Werth S, Abuharbeid S, et al. RNAi-mediated gene-targeting through systemic application of polyethyleneimine (PEI)-complexed siRNA in vivo. Gene Ther 2005;12(5):461-466
17. Wang Y, Gao S, Ye WH, et al. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self assembled from a biodegradable copolymer. Nat Mater 2006;5(10):791-796
18. Pridgen EM, Langer R, Farokhzad OC. Biodegradable polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine 2007;2(5):669-680
19. Zhang S, Xu Y, Wang B, et al. Cationic compounds used in lipoplexes and polyplexes for gene delivery. J Control Release 2004;100:165-180
20. Basarkar A, Singh J. Nanoparticulate systems for polynucleotide delivery. Int J Nanomed 2007;2(3):353-360
21. Elouahabi A, Ruysschaert JM. Formation and intracellular trafficking of lipoplexes and polyplexes. Mol Ther 2005;11:336-347
22. Ruponen M, Yla-Herttuala S, Urtti A. Interactions of polymeric and liposomal gene delivery systems with extracellular glycosaminoglycans: physicochemical and transfection studies. Biochim Biophys Acta 1999;1415:331-341
23. Gershon H, Ghirlando R, Guttman SB, Minsky A. Mode of formation and structural features of DNA-cationic liposome complexes used for transfection. Biochemistry 1993;32:7143-7151
24. Gao H, Hui KM. Synthesis of a novel series of cationic lipids that can act as efficient gene delivery vehicles through systematic heterocyclic substitution of cholesterol derivatives. Gene Ther 2001;8:855-863
25. Lv H, Zhang S, Wang B, et al. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006;114:100-109
26. El-Aneed A. An overview of current delivery systems in cancer gene therapy. J Control Release 2004;94:1-14
27. Pillai O, Panchagnula S. Polymers in drug delivery. Curr Opin Chem Biol 2001;5:447-451
28. Dodane V, Vilivalam VD. Pharmaceutical applications of chitosan. Pharm Sci Tech Today 1998;1:246-253
29. Hasegawa M, Yagi K, Iwakawa S, Hirai M. Chitosan induces apoptosis via caspase-3 activation in bladder tumor cells. Jpn J Cancer Res 2001;92:459-466
30. Chen WR, Adams RL, Carubelli R, Nordquist RE. Laserphotosensitizer assisted immunotherapy: a novel modality for cancer treatment. Cancer Lett 1997;115:25-30
31. Nishimura K, Nishimura S, Nishi N, et al. Immunological activity of chitin and its derivatives. Vaccine 1984;2:93-99
32. Murata J, Saiki I, Nishimura S. Inhibitory effect of chitin heparinoids on the lung metastasis of B16-BL6 melanoma. Jpn J Cancer Res 1989;80:866-872
33. Qi L, Xu Z, Chen M. In vitro and in vivo suppression of hepatocellular carcinoma growth by chitosan nanoparticles. Eur J Cancer 2007;43:184-193
34. Lin SY, Chan HY, Shen FH, et al. Chitosan prevents the development of AOM-induced aberrant crypt foci in mice and suppressed the proliferation of AGS cells by inhibiting DNA synthesis. J Cell Biochem 2007;100:1573-1580
35. Dass CR, Choong PFM. The use of chitosan formulations in cancer therapy. J Microencapsul 2008;25(4):275-279
36. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res 1998;15:1326-1331
37. Xu Y, Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm 2003;250:215-226
38. Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. J Drug Target 2008;16(2):108-123
39. Bozkir A, Saka OM. Chitosan nanoparticles for plasmid DNA delivery: effect of chitosan molecular structure on formulation and release characteristics. Drug Deliv 2004;11:107-112
40. Koping-Hoggard M, Tubulekas I, Guan H, et al. Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethyleneimine in vitro and after lung administration in vivo. Gene Ther 2001;8:1108-1121
41. Koping-Hoggard M, Varum KM, Issa M, et al. Improved chitosan mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers. Gene Ther 2004;11:1441-1452
42. Tan ML, Choong PFM, Dass CR. Cancer, chitosan nanoparticles and catalytic nucleic acids. J Pharm Pharmacol 2009;61:3-12
43. Min KH, Park K, Kim YS, et al. Hydrophobically-modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J Control Release 2008;127:208-218
44. Boussif O, Lezoualc'h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine, Proc Natl Acad Sci 1995; 92:7297-7301
45. Godbey WT, Wu KK, Mikos AG. Poly (ethylenimine) and its role in gene delivery. J Control Release 1999;60:149-160
46. Kunath K, von Harpe A, Fischer D. Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. J Control Release 2003;89:113-125
47. Lungwitz U, Breunig M, Blunk T, Goepferich A. Polyethylenimine based non-viral gene delivery systems. Eur J Pharm Biopharm 2005;60:247-266
48. Thomas M, Ge Q, Lu JJ, et al. Cross-linked small polyethylenimines: while still nontoxic, deliver DNA efficiently to mammalian cells in vitro and in vivo. Pharm Res 2005;22:373-380
49. Kim IS, Lee SK, Park YM, et al. Physicochemical characterization of poly (L-lactic acid) and poly(D,L-lactide-coglycolide) nanoparticles with polyethylenimine as gene delivery carrier. Int J Pharm 2005;298:255-262
50. Chollet P, Favrot MC, Hurbin A, et al. Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J Gene Med 2002;4:84-91
51. Moghimi SM, Symonds P, Murray JC, et al. A two-stage poly(ethylenimine)- mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther 2005;11:990-995
52. Godbey WT, Wu KK, Hirasaki GJ, Mikos AG. Improved packing of poly (ethyleneimine)/DNA complexes increases transfection efficiency. Gene Ther 1999;6:1380-1388
53. Godbey WT, Wu KK, Mikos AG. Poly (ethyleneimine)-mediated gene delivery affects endothelial cell function and viability. Biomaterials 2001;22:471-480
54. Fischer D, Bieber T, Li Y, et al. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 1999;16:1273-1279
55. Park MR, Han KO, Han IK, et al. Degradable polyethylenimine-altpoly (ethylene glycol) copolymers as novel gene carriers. J Control Release 2005;105:367-380
56. Zhong Z, Feijen J, Lok MC, et al. Low molecular weight linear polyethylenimine-b-poly(ethylene glycol)- b-polyethylenimine triblock copolymers: synthesis, characterization, and in vitro gene transfer properties. Biomacromolecules 2005; 6:3440-3448
57. Choi HS, Ooya T, Yui N. One-pot synthesis of a polyrotaxane via selective threading of a PEI-b-PEG-b-PEI copolymer. Macromol Biosci 2006;6:420-424
58. Kursa M, Walker GF, Roessler V, et al. Novel shielded transferrin polyethylene glycol-polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer. Bioconjug Chem 2003;14:222-231
59. Kircheis R, Schuller S, Brunner S, et al. Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. J Gene Med 1999;1:111-120
60. Xing J, Deng L, Guo S, et al. Polycationic nanoparticles as non-viral vectors employed for gene therapy in vivo. Mini Rev Med Chem 2010;10(2):126-137
61. Merdan T, Kunath K, Fischer D, et al. Intracellular processing of poly(ethylene imine)/ribozyme complexes can be observed in living cells by using confocal laser scanning microscopy and inhibitor experiments. Pharm Res 2002;19:140-146
62. Pouton CW, Lucas P, Thomas BJ, et al. Polycation-DNA complexes for gene delivery: a comparison of the biopharmaceutical properties of cationic polypeptides and cationic lipids. J Control Release 1998;53:289-299
63. Shewring L, Collins L, Lightman SL, et al. A nonviral vector system for efficient gene transfer to corneal endothelial cells via membrane integrins. Transplantation 1997;64:763-769
64. Ward CM, Read ML, Seymour LW. Systemic circulation of poly(L-lysine)/ DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapy. Blood 2001;97:2221-2229
65. Dash PR, Read ML, Barrett LB, et al. Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery. Gene Ther 1999;6:643-50 .. In vivo behavior of cationic polyplexes
66. Brown MD, Schatzlein A, Brownlie A, et al. Preliminary characterization of novel amino acid based polymeric vesicles as gene and drug delivery agents. Bioconjug Chem 2000;11:880-891
67. Nah JW, Yu L, Han SO, et al. Artery wall binding peptide-poly(ethylene glycol)-grafted-poly(L-lysine)-based gene delivery to artery wall cells. J Control Release 2002;78:273-284
68. Pichon C, Goncalves P. Midoux, Histidine-rich peptides and polymers for nucleic acids delivery. Adv Drug Deliv Rev 2001;53:75-94
69. Dubruel P, Christiaens B, Vanloo B, et al. Physicochemical and biological evaluation of cationic polymethacrylates as vectors for gene delivery. Eur J Pharm Sci 2003;18:211-220
70. Dubruel P, Christiaens B, Rosseneu M, et al. Buffering properties of cationic polymethacrylates are not the only key to successful gene delivery. Biomacromolecules 2004;5:379-388
71. Li P, Zhu JM, Sunintaboon P, et al. New route to amphiphilic coreshell polymer nanospheres: graft copolymerization of methyl methacrylate from water-soluble polymer chains containing amino groups. Langmuir 2002;18:8641-8646
72. Feng M, Lee D, Li P. Intracellular uptake and release of poly (ethyleneimine)-co-poly(methyl methacrylate) nanoparticle/ pDNA complexes for gene delivery. Int J Pharm 2006;311:209-214
73. Zhang S, Zhao B, Jiang H, et al. Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release 2007;123:1-10
74. Morille M, Passirani C, Vonarbaourg A, et al. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 2008;29:3477-3496
75. Putnam D, Gentry CA, Pack DW, Langer R. Polymer-plexes based gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc Natl Acad Sci USA 2001;98(3):1200-1205
76. Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 2002;54:715-758
77. Irie T, Uekama K. Cyclodextrins in peptide and protein delivery. Adv Drug Deliv Rev 1999;36(1):101-123
78. Wenz G, Han BH, Muller A. Cyclodextrin rotaxanes and polyrotaxanes. Chem Rev 2006;106(3):782-817
79. Ooya T, Ito A, Yui N. Preparation of alpha-cyclodextrin-terminated polyrotaxane consisting of beta-cyclodextrins and pluronic as a building block of a biodegradable network. Macromol Biosci 2005;5(5):379-383
80. Loethen S, Ooya T, Choi HS, et al. Synthesis, characterization, and pH-triggered dethreading of alphacyclodextrin- poly(ethylene glycol) polyrotaxanes bearing cleavable endcaps. Biomacromolecules 2006;7(9):2501-2506
81. Forrest ML, Gabrielson N, Pack DW. Cyclodextrin-polyethylenimine conjugates for targeted in vitro gene delivery. Biotechnol Bioeng 2005;89(4):416-423
82. Tang GP, Guo HY, Alexis F, et al. Low molecular weight polyethylenimines linked by betacyclodextrin for gene transfer into the nervous system. J Gene Med 2006;8(6):736-744
83. Yang C, Li HZ, Goh SH, Li J. Cationic star polymers consisting of a cyclodextrin core and oligoethylenimine arms as nonviral gene delivery vectors. Biomaterials 2007;28:3245-3254
84. Yang C, Wang X, Li HZ, et al. Synthesis and characterization of polyrotaxanes consisting of cationic alpha-cyclodextrin threaded on poly[(ethylene oxide)-ran- (propylene oxide)] as gene carriers. Biomacromolecules 2007;8:3365-3374
85. Ortega-Caballero F, Ortiz Mellet C, Le Gourrierec L, et al. Tailoring beta-cyclodextrin for DNA delivery by homogeneous functionalization at the secondary face. Org Lett 2008;10(22):5143-5146
86. Mendez-Ardoy A, Gomez-Garcia M, Ortiz Mellet C. Preorganized macromolecular gene delivery systems: amphiphilic beta-cyclodextrin 'click clusters'. Org Biomol Chem 2009;7:2681-2684
87. Diaz-Moscoso A, Le Gourrierec L, Gomez-Garcia M, et al. Polycationic amphiphilic cyclodextrins for gene delivery: synthesis and effect of structural modifications on plasmid DNA complex stability, cytotoxicity and gene expression. Chem Eur J 2010;15(46):12871-12878
88. Diaz-Moscoso A, Balbuena P, Gomez-Garcia M, et al. Rational design of cationic cyclooligosaccharides as efficient gene delivery systems. Chem Commun 2008;17:2001-2003
89. Lynn D, Langer R. Degradable Poly (beta-amino esters): synthesis, characterization, and self-assembly with plasmid DNA. J Am Chem Soc 2000;122:10761-10768
90. Little SR, Lynn DM, Ge Q, et al. Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc Natl Acad Sci USA 2004;101:9534-9539
91. Little SR, Lynn DM, Puram SV, et al. Formulation and characterization of poly (beta amino ester) microparticles for genetic vaccine delivery. J Control Release 2005;107:449-462
92. Shenoy D, Little S, Langer R, Amiji M. Poly(ethylene oxide) modified poly(betaaminoester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies. Pharm Res 2005;22(12):2107-2114
93. Yatav S, van Vlerken LE, Little SR, Amiji MM. Evaluation of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol 2009;63:711-722
94. van Vlerken LE, Duan Z, Little SR, et al. Biodistribution and pharmacokinetic analysis of paclitaxel and ceramide administration in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model. Mol Pharm 2008;5(4):516-526
95. Devalapally H, Shenoy D, Little S, et al. Poly(ethylene oxide) modified poly(betaaminoester) nanoparticles as a pH-sensitive system for tumor targeted delivery of hydrophobic drugs. Part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. Cancer Chemother Pharmacol 2007;59:477-484
96. Xiong XB, Uludaǧ H, Lavasanifar A. Biodegradable amphiphilic poly(ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarriers for efficient siRNA delivery. Biomaterials 2009;30:242-253
97. Gao X, Huang L. Potentiation of cationic liposome mediated gene delivery by polycations. Biochemistry 1996;35:1027-1036
98. Hofland HE, Shephard L, Sullivan SM. Formation of stable cationic lipid/ DNA complexes for gene transfer. Proc Natl Acad Sci USA 1996;93:7305-7309
99. Wang CY, Huang L. pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse. Proc Natl Acad Sci USA 1987;84:7851-7855
100. Guo W, Lee T, Sudimack J, Lee RJ. Receptor-specific delivery of liposomes via folate-PEG-chol. J Liposome Res 2000;10:179-195
101. Xu L, Pirollo KF, Chang EH. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J Control Release 2001;74:115-128
102. Li W, Szoka FC. Lipid-based nanoparticles of nucleic acid delivery. Pharm Res 2007;24(3):438-449
103. Van deWetering P, Schuurmans-Nieuwenbroek NM, Hennink WE, Storm G. Comparative transfection studies of human ovarian carcinoma cells in vitro, ex vivo and in vivo with poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes. J Gene Med 1999;1:156-165
104. Wolfert MA, Schaht EH, Tonceva V, et al. Characterization of vectors for gene therapy formed by self assembly of DNA with synthetic block co-polymers. Hum Gene Ther 1996;7:2123-2133
105. Wang L, Kristensen J, Ruffner DE. Delivery of antisense oligonucleotides using HPMA polymer: synthesis of A thiol polymer and its conjugation to water-soluble molecules. Bioconjug Chem 1998;9:749-757
106. Jensen KD, Kopeckova P, Bridge JHB, Kopecek J. The cytoplasmic escape and nuclear accumulation of endocytosed and microinjected HPMA copolymers and a basic kinetic study in Hep G2 cells. AAPS Pharm Sci 2001;3(4):62-75
107. Subr V, Konak C, Laga R, Ulbrich K. Coating of DNA/poly(L-lysine) complexes by covalent attachment of poly[N-(2-hydroxypropyl) methacrylamide]. Biomacromolecules 2006;7:122-130
108. Scales CW, Huang F, Li N, et al. Corona-stabilized interpolyelectrolyte complexes of siRNA with nonimmunogenic, hydrophilic/cationic block copolymers prepared by aqueous RAFT polymerization. Macromolecules 2006;39:6871-6881
109. Li SD, Chono S, Huang L. Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release 2008;126(1):77-84
110. Lemarchand C, Gref R, Couvreur P. Polysaccharide decorated nanoparticles. Eur J Pharm Biopharm 2004;58:327-341
111. Ito A, Shinkai M, Honda H, Kobayashi T. Medical application of magnetic functionalized nanoparticles. J Biosci Eng 2005;10(1):1-11
112. Shinkai M, Yanase M, Honda H, et al. Intracellular hyperthermia for cancer using magnetite cationic liposome: in vitro study. Jpn J Cancer Res 1996;87:1179-1183
113. Suzuki M, Shinkai M, Honda H, Kobayashi T. Anticancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes. Melanoma Res 2003;13:129-135
114. Yanase M, Shinkai M, Honda H, et al. Intracellular hyperthermia for cancer using magnetite cationic liposomes: an in vivo study. Jpn J Cancer Res 1998;89:463-469 (Pubitemid 28226929)
115. Matsuoka F, Shinkai M, Honda H, et al. Hyperthermia using magnetite cationic liposomes for hamster osteosarcoma. Biomagn Res Technol 2004;2(3):1-6
116. Matsuno H, Tohnai I, Mitsudo K, et al. Interstitial hyperthermia using magnetite cationic liposomes inhibit to tumor growth of VX-7 transplanted tumor in rabbit tongue. Jpn J Hyperthermic Oncol 2001;17:141-149
117. Duan J, Zhang Y, Chen W, et al. Cationic polybutylcyanoacrylate nanoparticles for DNA delivery. J Biomed Biotechnol 2009; doi:10.1155/2009/ 149254
118. Pille JY, Li H, Blot E, et al. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum Gene Ther 2006;17:1019-1026
119. Yang SC, Ge HX, Hu Y, et al. Formation of positively charged poly (butyl cyanoacrylate) nanoparticles stabilized with chitosan. Colloid Polym Sci 2000;278:285-292
120. Bilensoy E, Sarisözen C, Esendaǧli G, et al. Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors. Int J Pharm 2009;371:170-176
121. Peetla C, Labhasetwar V. Effect of molecular structure of cationic surfactants on biophysical interactions of surfactant-modified nanoparticles with a model membrane and cellular uptake. Langmuir 2009;25:2369-2377
122. Bhardwaj V, Ankola DD, Gupta SC, et al. PLGA nanoparticles stabilized with a cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm Res 2009;26(11):2495-2503
123. Baoum A, Dhillon N, Buch S, Berkland C. Cationic surface modification of PLG nanoparticles offers sustained gene delivery to pulmonary epithelial cells. J Pharm Sci 2010;99(5):2413-2422
124. Diaz S, Navarro G, Tros de Ilarduya C, et al. In vivo targeted gene delivery by cationic nanparticles for treatment of hepatocellular carcinoma. J Gene Med 2009;11:38-45
125. Diez S, Migueliz G, Tros de Ilarduya C, et al. Targeted cationic Poly(D,L-Lactic- Co-Glycolic Acid) nanoparticles for gene delivery to cultured cells. Cell Mol Biol Lett 2009;14:347-362
126. Gillies R, Frechet JMJ. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 2005;10(1):35-43
127. Patri AK, Kukowska-Latallo JF, Baker JR Jr. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev 2005;57:2203-2214
128. Zuber G, Dauty E, Nothisen M, et al. Towards synthetic viruses. Adv Drug Deliv Rev 2001;52(3):245-253
129. Luo D, Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol 2000;18(1):33-37
130. Rudolph C, Muller RH, Rosenecker J. Jet nebulization of PEI/DNA polyplexes: physical stability and in vitro gene delivery efficiency. J Gene Med 2002;4(1):66-74
131. Wu YJ, Noguchi CT. Cloning of cDNA from induced K562 cells which can activate globin gene expression. Prog Clin Biol Res 1989;316A:313-321
132. Sorgi FL, Bhattacharya S, Huang L. Protamine sulfate enhances lipid-mediated gene transfer. Gene Ther 1997;4(9):961-968 (Pubitemid 27437722)
133. Schwartz B, Ivanov MA, Pitard B, et al. Synthetic DNA-compacting peptides derived from human sequence enhance cationic lipid-mediated gene transfer in vitro and in vivo. Gene Ther 1999;6(2):282-292
134. Wagner S, Knippers R. An SV40 large T antigen binding site in the cellular genome is part of a cis-acting transcriptional element. Oncogene 1990;5(3):353-359
135. Zauner W, Farrow NA, Haines AM. In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density. J Control Release 2001;71(1):39-51
136. Zelphati O, Uyechi LS, Barron LG, Szoka FC Jr. Effect of serum components on the physico-chemical properties of cationic lipid/ oligonucleotide complexes and on their interactions with cells. Biochim Biophys Acta 1998;1390(2):119-133
137. Tang MX, Szoka FC. The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes. Gene Ther 1997;4(8):823-832
138. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002;54(5):631-651
139. Passirani C. Complement activation by injectable colloidal drug carriers. In: Mahato RI, editor, Biomaterials for delivery and targeting of proteins and nucleic acids. CRC Press, Boca Raton; 2005. p. 187-230
140. Muller-Eberhard HJ. Molecular organization and function of the complement system. Annu Rev Biochem 1988;57:321-347
141. Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable long-circulating polymeric nanospheres. Science 1994;263(5153):1600-1603
142. Vonarbourg A, Passirani C, Saulnier P, Benoit JP. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 2006;27(24):4356-4373
143. Li J, Loh XJ. Cyclodextrin based supramolecular architectures: syntheses, structures and application for drug and gene delivery. Adv Drug Deliv Rev 2008;60:1000-1017